Through December 2014, Dr. Krenitsky was chief commercial officer & SVP of International Strategy and previously chief operating officer of Foundation Medicine. He joined Foundation in June 2011 and was instrumental in taking the company from a start-up organization to a successful IPO in 2013, followed by a major 1.2B investment by Roche making them majority stakeholders. Prior to Foundation Medicine, he served as president of Enzo Clinical Labs, where he instituted a comprehensive strategic and operational plan that led to the introduction and launch of numerous FDA-approved esoteric tests, as well as several new laboratory developed tests. Dr. Krenitsky served as chief executive officer at both BioServe Biotechnologies, a global biotechnology company specializing in processing genetic diagnostic tests, and Parkway Clinical Laboratories, a clinical diagnostic lab providing comprehensive routine and esoteric testing. He also held various senior-level positions within Genomics Collaborative, Inc. (a SeraCare Life Sciences Company), a full-scale clinical and genomics research company. Dr. Krenitsky received a B.S. in business management from the University of Scranton and an M.D. from Jefferson Medical College (now the Sidney Kimmel Medical College) in Philadelphia. He is a former member of the Board of Directors of the New York State Clinical Lab Association and of BioServe Biotechnologies, and serves on the Board of Directors of Lumicell.
NeuroPointDX is a division of Stemina Biomarker Discovery. Each of the members of our Board of Directors provides strong leadership and experience to both divisions of our business.